menu
    • menu
    [{"orgOrder":0,"company":"ACEA Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Abivertinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"ACEA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ACEA Therapeutics \/ Sorrento","highestDevelopmentStatusID":"10","companyTruncated":"ACEA Therapeutics \/ Sorrento"},{"orgOrder":0,"company":"ACEA Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Merger","leadProduct":"Abivertinib","moa":"TYK","graph1":"Oncology","graph2":"Phase III","graph3":"ACEA Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"Capsule","sponsorNew":"ACEA Therapeutics \/ Sorrento","highestDevelopmentStatusID":"10","companyTruncated":"ACEA Therapeutics \/ Sorrento"},{"orgOrder":0,"company":"ACEA Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Abivertinib","moa":"TYK","graph1":"Oncology","graph2":"Phase III","graph3":"ACEA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ACEA Therapeutics \/ Sorrento","highestDevelopmentStatusID":"10","companyTruncated":"ACEA Therapeutics \/ Sorrento"},{"orgOrder":0,"company":"ACEA Therapeutics","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Lidocaine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ACEA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ACEA Therapeutics \/ ACEA Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"ACEA Therapeutics \/ ACEA Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by ACEA Therapeutics

    Menu

    ACEA Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ACEA Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            ACEA Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Scilex Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Scilex and ACEA Collaborate to Expand ZTlido® in ex-US and Far East Markets

                            Details : Under the agreement terms, ACEA will receive exclusive rights to develop and commercialize ZTlido (lidocaine)for the relief of neuropathic pain associated with post-herpetic neuralgia.

                            Brand Name : Ztlido

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 17, 2024

                            Lead Product(s) : Lidocaine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Scilex Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ACEA Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            ACEA Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abivertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Sorrento Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise

                            Details : This is a value-inflection acquisition for Sorrento as it brings in multiple NCE drug product candidates, including the previously licensed Abivertinib as an anchoring small molecule drug product for treating many different cancers and autoimmune disease...

                            Brand Name : STI-5656

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 02, 2021

                            Lead Product(s) : Abivertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Sorrento Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ACEA Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            ACEA Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abivertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Sorrento Therapeutics

                            Deal Size : $450.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics

                            Details : The acquisition will include late clinical stage drug Abivertinib, clinical stage candidate AC0058, preclinical stage candidate AC0939, and ACEA’s extensive proprietary library of small molecules, which potentially have applications for numerous human ...

                            Brand Name : STI-5656

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 05, 2021

                            Lead Product(s) : Abivertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Sorrento Therapeutics

                            Deal Size : $450.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ACEA Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            ACEA Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abivertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Sorrento Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sorrento Acquired Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell L...

                            Details : Sorrento gets an exclusive license to ACEA’s Abivertinib, a novel small molecule tyrosine kinase inhibitor that selectively targets both mutant forms of the epidermal growth factor receptor and Bruton’s tyrosine kinase, across all indications for all...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 21, 2020

                            Lead Product(s) : Abivertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Sorrento Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth